Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERVGet Free Report) in a research report issued on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright cut their price target on shares of Minerva Neurosciences from $11.00 to $7.00 and set a “neutral” rating for the company in a report on Thursday, May 2nd.

View Our Latest Analysis on Minerva Neurosciences

Minerva Neurosciences Trading Down 0.3 %

Shares of NERV opened at $3.21 on Tuesday. The stock has a market cap of $22.45 million, a PE ratio of -0.72 and a beta of 0.13. Minerva Neurosciences has a 1 year low of $2.26 and a 1 year high of $13.49. The stock has a 50 day simple moving average of $2.55 and a 200-day simple moving average of $4.88.

Minerva Neurosciences (NASDAQ:NERVGet Free Report) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.07. On average, sell-side analysts forecast that Minerva Neurosciences will post -1.89 EPS for the current fiscal year.

About Minerva Neurosciences

(Get Free Report)

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.

Featured Articles

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.